AstraZeneca plc (AZN) Ordinary US$0.25
78.00p
(0.58%)
- Add to watchlist
- Create an alert
- This stock can be held in a
78.00p
(0.58%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
78.00p
(0.58%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
AstraZeneca secures US approval for Imfinzi in gastric cancer
26 November 2025 07:03
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that its Imfinzi asset has been approved in the US for use alongside standard FLOT chemotherapy in the treatment of adult patients with resectable,...
-
AstraZeneca to spend $2bn in US manufacturing push
24 November 2025 07:01
(Sharecast News) - AstraZeneca is to invest $2bn ramping up manufacturing facilities in Maryland, America, the blue chip drugs giant said on Monday.
-
AstraZeneca receives FDA approval for expanded Koselugo usage
20 November 2025 07:12
(Sharecast News) - The US Food and Drug Administration has approved the expanded usage of AstraZeneca's Koselugo drug to adults with neurofibromatosis type 1 (NF1) - a rare, progressive, genetic...
-
Director dealings: 3i execs buy the dip, AstraZeneca CFO offloads shares
14 November 2025 13:53
(Sharecast News) - London-listed companies 3i Group and AstraZeneca disclosed fresh director dealings on Wednesday, with senior executives at the private equity group adding to their holdings while...
-
AstraZeneca beats Q3 expectations, maintains FY outlook
6 November 2025 09:18
(Sharecast News) - Drugmaker AstraZeneca reiterated its full-year guidance on Thursday as it posted a third-quarter earnings beat, driven by solid sales of its cancer, heart and kidney disease drugs.
-
AstraZeneca's Koselugo receives EU approval
28 October 2025 07:03
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Koselugo asset has been approved for usage in the European Union for the rare, progressive, genetic condition, plexiform neurofibromas, in...
-
Astrazeneca's Tezspire secures EU approval
22 October 2025 08:00
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that its chronic rhinosinusitis with nasal polyps treatment, Tezspire, has been approved in the European Union as an add-on therapy with intranasal...
-
AstraZeneca lupus treatment gets EU approval
20 October 2025 07:03
(Sharecast News) - AstraZeneca has received the green light from European regulators for its Saphnelo treatment for lupus, the pharma giant announced on Monday.
-
Deutsche Bank downgrades AstraZeneca to 'sell'
16 October 2025 10:24
(Sharecast News) - Deutsche Bank downgraded AstraZeneca to 'sell' from 'hold' on Thursday and cut the price target to 10,500p from 11,500p as it said it was turning sceptical on SERENA-4.
-
AstraZeneca to cut US drug prices in key White House deal
13 October 2025 07:01
(Sharecast News) - AstraZeneca has struck a deal with the White House to cut drugs prices in America, allowing it to avoid steep tariffs on US imports.
-
AstraZeneca's Baxdrostat hits Phase III endpoint in resistant hypertension
7 October 2025 07:27
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that Baxdrostat had met its primary endpoint in the Bax24 Phase III trial, delivering a "statistically significant and clinically meaningful...
-
London midday: Stocks mixed with French and US fiscal impasses in focus
6 October 2025 11:13
(Sharecast News) - Stocks in London were trading on a mixed note around the midday mark, but had stabilised despite news of the French Prime Minister's resignation after just a month on the job.
Company announcements Announcements
-
Holding(s) in Company
4 December 2025 15:00
AstraZeneca
-
Block listing Interim Review
1 December 2025 15:05
AstraZeneca
-
Total Voting Rights
1 December 2025 15:00
AstraZeneca
-
Imfinzi approved in US for early gastric cancer
26 November 2025 07:00
AstraZeneca
-
AstraZeneca manufacturing investment in Maryland
24 November 2025 07:00
AstraZeneca
-
Koselugo (selumetinib) approved in the US
20 November 2025 07:00
AstraZeneca
-
Holding(s) in Company
17 November 2025 15:00
AstraZeneca
-
Director/PDMR Shareholding
14 November 2025 11:00
AstraZeneca
-
Director/PDMR Shareholding
10 November 2025 15:00
AstraZeneca
-
9M and Q3 2025 results
6 November 2025 07:00
AstraZeneca
-
Result of General Meeting
3 November 2025 16:00
AstraZeneca
-
Total Voting Rights
3 November 2025 15:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.